ANGION BIOMEDICA CORPORATION

Basic Information

51 Charles Lindbergh Blvd
Uniondale, NY, 11553-3658

Company Profile

n/a

Additional Details

Field Value
DUNS: 53129065
Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N
Number of Employees: 31


  1. A Novel Small Molecule Therapeutic for Alcoholic Chronic Pancreatitis

    Amount: $224,347.00

    DESCRIPTION (provided by applicant): Chronic Pancreatitis (CP) is characterized by continuous or recurrent inflammation of the pancreas that leads to permanent destruction of the pancreas resulting in ...

    SBIR Phase I 2014 Department of Health and Human Services
  2. A Therapeutic for Radiation Induced Lung Injury

    Amount: $299,948.00

    DESCRIPTION (provided by applicant): Nuclear accidents and terrorism present a serious threat for causing mass-casualty scenarios. In radiation events, many people receive non-uniform whole-body or pa ...

    SBIR Phase I 2014 Department of Health and Human Services
  3. PDGFR and KDR Inhibitors for Liver Fibrosis

    Amount: $769,978.00

    ? DESCRIPTION (provided by applicant): The incidence and prevalence of both alcoholic and non-alcoholic liver diseases is increasing. The population presenting with Metabolic Syndrome, a key risk ...

    SBIR Phase II 2014 Department of Health and Human Services
  4. SBIR Phase I: A Novel Extended Delivery Dual-action Platform for Peptide-based Anti-fibrotics

    Amount: $149,761.00

    This Small Business Innovation Research (SBIR) Phase I project seeks to develop a new drug-delivery microscaffold that can help millions of patients suffering from chronic kidney, liver or lung diseas ...

    SBIR Phase I 2014 National Science Foundation
  5. A collagen wound dressing augmented with a proteoglycan mimic to enhance chronic

    Amount: $251,048.00

    DESCRIPTION (provided by applicant): Liver fibrosis is a form of scar formation that is found in almost all patients with chronic injury to the liver. Over time it frequently progresses to cirrhosis, ...

    SBIR Phase I 2013 Department of Health and Human Services
  6. Aldosterone Synthase Inhibitor for CKD

    Amount: $380,911.00

    DESCRIPTION (provided by applicant): The renin-angiotensin-aldosterone system (RAAS) plays a critical role in renal physiology. Inhibitors of angiotensin-converting enzyme (ACE) or angiotensin recepto ...

    SBIR Phase I 2013 Department of Health and Human Services
  7. A Novel Therapeutic for Liver Fibrosis

    Amount: $2,087,768.00

    DESCRIPTION (provided by applicant): Alcoholic and non-alcoholic liver fibrosis remains an unsolved challenge for the hepatologist as it can lead to cirrhosis and end-stage liver disease, a life-threa ...

    SBIR Phase II 2012 Department of Health and Human Services
  8. Anti-Fibrotic Therapy for Scleroderma/SSc

    Amount: $2,809,486.00

    DESCRIPTION (provided by applicant): Scleroderma (also known as systemic sclerosis-SSc) is characterized primarily by progressive dermal and vascular fibrosis. Other organs are affected too, includin ...

    SBIR Phase II 2012 Department of Health and Human Services
  9. Antifibrotic Therapy for Chronic Kidney Disease

    Amount: $1,780,804.00

    DESCRIPTION (provided by applicant): Chronic kidney disease (CKD) remains an unsolved challenge for the nephrologist, as it almost inevitably leads to end-stage renal failure, a life-threatening condi ...

    SBIR Phase II 2012 Department of Health and Human Services
  10. Novel Neuroprotective/Restorative Therapy for Ischemic Stroke

    Amount: $1,194,283.00

    DESCRIPTION (provided by applicant): Ischemic Stroke continues to be a major cause of morbidity and mortality in the United States. Currently approved thrombolytic therapy suffers for a narrow therape ...

    SBIR Phase II 2012 Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government